Dataset Information

Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes-A single-centre, prospective, controlled observational study.

ABSTRACT:

Introduction

To investigate the glycaemic response, macronutrient intake and insulin management in people with type 1 diabetes (T1D) compared to healthy individuals around a running competition.

Material and methods

This was a single-centre, prospective, controlled observational study performed in individuals with T1D and healthy people. 24 people (12 T1D) were included in this study (age: T1D 41±12 vs. healthy 38±6 years, females: 3 vs. 6, BMI: 25.53.0 vs. 22.9±2.8 kg/m2). Both groups received an intermittently scanned continuous glucose monitoring (isCGM; FreeStyle Libre 1, Abbott, USA) system to assess glycaemia 24 hours before, during and 24 hours after a running competition. During this period, participants recorded their food intake and insulin administration. Data were analysed via ANOVA and mixed model analyses with post-hoc testing (p≤0.05).

Results

For overall glycaemic ranges in comparison of groups, significant differences were found for time in range (T1D 63±21% vs. healthy 89±13%, p = 0.001), time above range (TAR) 1 (T1D 21±15% vs. healthy 0±0%, p<0.001) and TAR 2 (T1D 8 [0-16%] vs. healthy 0±0%, p<0.001). When glycaemic variability was assessed, people with T1D had a higher glycaemic variability compared to healthy individuals (p<0.0001). Basal insulin dose was significantly reduced when compared against the regular pre-study basal insulin dose (pre-study 22±6 vs. pre-competition day 11±9 (-50±41%), p = 0.02; competition day 15±5 (-32± 1%)).

Conclusion

People with T1D have impaired glucose responses around a running competition compared to healthy individuals. However, basal insulin dose reductions were sufficient to prevent further dysglycaemia.

Clinical trial id

drks.de; DRKS00019886.

SUBMITTER: Moser O

PROVIDER: S-EPMC7485886 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes-A single-centre, prospective, controlled observational study.

Moser Othmar O Mueller Alexander A Eckstein Max L ML Ziko Haris H Aberer Felix F Treiber Gerlies G Unteregger Christina C Kojzar Harald H Mader Julia K JK Sourij Caren C Pferschy Peter P Obermayer Anna A Tripolt Norbert N Sourij Harald H

PloS one 20200911 9

<h4>Introduction</h4>To investigate the glycaemic response, macronutrient intake and insulin management in people with type 1 diabetes (T1D) compared to healthy individuals around a running competition.<h4>Material and methods</h4>This was a single-centre, prospective, controlled observational study performed in individuals with T1D and healthy people. 24 people (12 T1D) were included in this study (age: T1D 41±12 vs. healthy 38±6 years, females: 3 vs. 6, BMI: 25.53.0 vs. 22.9±2.8 kg/m2). Both g ...[more]

PMID: 32915897

Similar Datasets

Project description:BackgroundThe percentage of sustained maximal oxygen uptake and the running economy are important factors that determine the running success of endurance athletes. Running economy is defined as the oxygen uptake required to run at a given speed and depends on metabolic, cardiorespiratory, biomechanical, neuromuscular, and anthropometric factors. With regard to anthropometric characteristics, total body mass seems to be a crucial factor for the running economy. Moreover, neuromuscular components, especially knee muscular strength and the strength balance ratio, also seem to be critical for the running economy. In addition to knee muscle strength, hip muscle strength is also an important contributor to running performance on level or hilly ground. However, the relationship between running economy and the hip muscles is unknown. Thus the aim of the present study was to verify whether hip flexor and extensor isokinetic peak torque, the isokinetic strength balance ratio, total body mass and fat free mass were associated with running economy in both sexes and to compare sex differences in physical fitness and isokinetic strength characteristics.MethodsA total of 24 male (31.0 ± 7.7 years, 176.2 ± 7.3 cm, and 70.4 ± 8.4 kg) and 15 female (31.3 ± 6.7 years, 162.9 ± 3.9 cm, and 56.0 ± 5.3 kg) recreationally-trained endurance runners were recruited. Maximal oxygen uptake, running economy, conventional (concentric flexors-to-concentric extensors) and functional (concentric flexors-to-eccentric extensors) hip isokinetic strength balance ratios, peak torque of the hip flexor and extensor muscles, total body mass, and fat-free mass were measured. Running economy was assessed on two separate days by means of the energy running cost (Ec) using a motorized treadmill at 10.0 and 12.0 km h-1 (3% gradient) and 11.0 and 14.0 km h-1 (1% gradient).ResultsThe functional balance ratio was significantly and negatively associated with Ec at 11.0 (r = - 0.43, P = 0.04) and 12.0 km h-1 (r = - 0.65, P = 0.04) when using a 3% gradient in male runners. Considering muscular strength, male runners only showed a significant relationship between Ec (assessed at 12 km h-1 and a 3% gradient) and peak torque for extensor muscle eccentric action (r = 0.72, P = 0.04). For female runners, only peak torque relative to total body mass for extensor muscles (180° s-1) was positively associated with Ec when assessed at 10 km h-1 using a 3% gradient (r = 0.59, P = 0.03). No significant relationships were found between Ec and total body mass or fat-free mass.DiscussionGiven that the functional balance ratio was associated with a better Ec, coaches and athletes should consider implementing a specific strengthening program for hip flexor muscles to increase the functional ratio.

Project description:IntroductionPatients with type 2 diabetes (T2D) who require intensification of basal insulin therapy need treatment options that can improve their health-related quality of life (HRQoL) and translate into better outcomes. These analyses compared patient-reported outcomes (PROs) in patients with T2D receiving tirzepatide or insulin lispro.MethodsThe randomised, open-label, multinational, phase 3b SURPASS-6 trial (NCT04537923) was conducted at 135 medical research centres and hospitals in 15 countries and compared two recommended treatment intensification strategies in people with T2D and inadequate glycaemic control on basal insulin: addition of once-weekly tirzepatide versus addition of prandial insulin lispro. Randomisation was stratified by country, baseline glycated haemoglobin level and metformin use. PROs were measured using the Short Form-36 Health Survey version 2 (SF-36v2) acute form (secondary outcome), EQ-5D-5L, Ability to Perform Physical Activities of Daily Living (APPADL) questionnaire and Impact of Weight on Self-Perceptions (IW-SP) questionnaire (tertiary/exploratory outcomes). PROs were compared for the tirzepatide-pooled dose group (5, 10 and 15 mg) and each tirzepatide dose group versus insulin lispro at 52 weeks using the modified intention-to-treat efficacy analysis set.ResultsBetween 19 October 2020 and 01 November 2022, 2267 people were assessed and 1428 participants with T2D were randomised. At 52 weeks, participants in the tirzepatide-pooled group had statistically significant improved scores across all SF-36v2 domains and both component summary scores compared with insulin lispro-treated participants (p < 0.05), with the largest differences observed in the general health, vitality and mental health domains. Statistically significant improved APPADL and IW-SP total scores, as well as EQ visual analogue scale and EQ-5D-5L index scores (after adjustment for baseline scores), were observed in tirzepatide-pooled participants compared with insulin lispro-treated participants.ConclusionsIn adult patients with T2D and inadequate glycaemic control with basal insulin, tirzepatide treatment was associated with greater improvements in HRQoL than prandial insulin therapy in addition to clinically significant improvements in glycaemic and body weight-related parameters.

Dataset Information

Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes-A single-centre, prospective, controlled observational study.

Introduction

Material and methods

Results

Conclusion

Clinical trial id

Publications

Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes-A single-centre, prospective, controlled observational study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets